A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

NCT05497453 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate after monotherapy dose escalation.

Conditions

Hepatocellular Carcinoma
Solid Tumor
Hepatocellular Carcinoma Non-resectable
Hepatocellular Carcinoma Recurrent
Hepatocellular Cancer
Liver Cancer
Liver, Cancer Of, Non-Resectable

Interventions

DRUG: OTX-2002
DRUG: Tyrosine kinase inhibitor One
DRUG: Tyrosine kinase inhibitor Two
DRUG: Checkpoint Inhibitor, Immune

Sponsor

Omega Therapeutics